全文获取类型
收费全文 | 771篇 |
免费 | 64篇 |
国内免费 | 1篇 |
出版年
2021年 | 7篇 |
2018年 | 7篇 |
2017年 | 7篇 |
2016年 | 13篇 |
2015年 | 26篇 |
2014年 | 33篇 |
2013年 | 26篇 |
2012年 | 38篇 |
2011年 | 44篇 |
2010年 | 33篇 |
2009年 | 19篇 |
2008年 | 29篇 |
2007年 | 21篇 |
2006年 | 12篇 |
2005年 | 19篇 |
2004年 | 18篇 |
2003年 | 16篇 |
2002年 | 19篇 |
2001年 | 14篇 |
2000年 | 16篇 |
1999年 | 14篇 |
1998年 | 11篇 |
1997年 | 10篇 |
1996年 | 7篇 |
1995年 | 9篇 |
1994年 | 7篇 |
1992年 | 15篇 |
1991年 | 18篇 |
1990年 | 26篇 |
1989年 | 20篇 |
1988年 | 16篇 |
1987年 | 8篇 |
1986年 | 11篇 |
1985年 | 14篇 |
1984年 | 15篇 |
1983年 | 17篇 |
1982年 | 9篇 |
1981年 | 7篇 |
1980年 | 6篇 |
1977年 | 8篇 |
1976年 | 13篇 |
1975年 | 13篇 |
1974年 | 9篇 |
1973年 | 11篇 |
1972年 | 6篇 |
1971年 | 14篇 |
1970年 | 10篇 |
1969年 | 11篇 |
1968年 | 6篇 |
1967年 | 8篇 |
排序方式: 共有836条查询结果,搜索用时 15 毫秒
81.
Idell S Allen T Chen S Koenig K Mazar A Azghani A 《American journal of physiology. Lung cellular and molecular physiology》2007,293(1):L25-L32
High levels of adenosine can be measured from the lungs of asthmatics, and it is well recognized that aerosolized 5'AMP, the precursor of adenosine, elicits robust bronchoconstriction in patients with this disease. Characterization of mice with elevated adenosine levels secondary to the loss of adenosine deaminase (ADA) expression, the primary metabolic enzyme for adenosine, further support a role for this ubiquitous mediator in the pathogenesis of asthma. To begin to identify pathways by which adenosine can alter airway tone, we examined adenosine-induced bronchoconstriction in four mouse lines, each lacking one of the receptors for this nucleoside. We show, using direct measures of airway mechanics, that adenosine can increase airway resistance and that this increase in resistance is mediated by binding the A(1) receptor. Further examination of this response using pharmacologically, surgically, and genetically manipulated mice supports a model in which adenosine-induced bronchoconstriction occurs indirectly through the activation of sensory neurons. 相似文献
82.
The objective of this study was to determine the prevalence, mutual associations, clinical manifestations, and diagnoses associated
with serum autoantibodies, as detected using recently available immunoassays, in patients with autoimmune myositis (AIM).
Sera and clinical data were collected from 100 patients with AIM followed longitudinally. Sera were screened cross-sectionally
for 21 autoantibodies by multiplex addressable laser bead immunoassay, line blot immunoassay, immunoprecipitation of in vitro translated recombinant protein, protein A assisted immunoprecipitation, and enzyme-linked immunosorbent assay. Diagnoses
were determined using the Bohan and Peter classification as well as recently proposed classifications. Relationships between
autoantibodies and clinical manifestations were analyzed by multiple logistic regression. One or more autoantibodies encompassing
19 specificities were present in 80% of the patients. The most common autoantibodies were anti-Ro52 (30% of patients), anti-Ku
(23%), anti-synthetases (22%), anti-U1RNP (15%), and anti-fibrillarin (14%). In the presence of autoantibodies to Ku, synthetases,
U1RNP, fibrillarin, PM-Scl, or scleroderma autoantigens, at least one more autoantibody was detected in the majority of sera
and at least two more autoantibodies in over one-third of sera. The largest number of concurrent autoantibodies was six autoantibodies.
Overall, 44 distinct combinations of autoantibodies were counted. Most autoantibodies were unrestricted to any AIM diagnostic
category. Distinct clinical syndromes and therapeutic responses were associated with anti-Jo-1, anti-fibrillarin, anti-U1RNP,
anti-Ro, anti-Ro52, and autoantibodies to scleroderma autoantigens. We conclude that a significant proportion of AIM patients
are characterized by complex associations of autoantibodies. Certain myositis autoantibodies are markers for distinct overlap
syndromes and predict therapeutic outcomes. The ultimate clinical features, disease course, and response to therapy in a given
AIM patient may be linked to the particular set of associated autoantibodies. These results provide a rationale for patient
profiling and its application to therapeutics, because it cannot be assumed that the B-cell response is the same even in the
majority of patients in a given diagnostic category. 相似文献
83.
He Y Kamenecka TM Shin Y Song X Jiang R Noel R Duckett D Chen W Ling YY Cameron MD Lin L Khan S Koenig M LoGrasso PV 《Bioorganic & medicinal chemistry letters》2011,21(6):1719-1723
Quinazoline 3 was discovered as a novel c-jun N-terminal kinase (JNK) inhibitor with good brain penetration and pharmacokinetic (PK) properties. A number of analogs which were potent both in the biochemical and cellular assays were discovered. Quinazoline 13a was found to be a potent JNK3 inhibitor (IC50 = 40 nM), with >500-fold selectivity over p38, and had good PK and brain penetration properties. With these properties, 13a is considered a potential candidate for in vivo evaluation. 相似文献
84.
Schmidt RG Bayburt EK Latshaw SP Koenig JR Daanen JF McDonald HA Bianchi BR Zhong C Joshi S Honore P Marsh KC Lee CH Faltynek CR Gomtsyan A 《Bioorganic & medicinal chemistry letters》2011,21(5):1338-1341
Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition. 相似文献
85.
Gregory H. Golet Thomas Gardali John W. Hunt David A. Koenig Neal M. Williams 《Restoration Ecology》2011,19(1):126-135
Evaluating the success of restoration projects requires well‐designed studies. Among the decisions that need to be made are what taxonomic groups to study and when to conduct the monitoring. To explore how these decisions can influence assessments of restoration success, we examined species richness and composition data collected over several years on different terrestrial fauna (landbirds, rodents, bees, and beetles) at Sacramento River restoration and remnant riparian sites. Our selection of study organisms enabled us to ask whether variability in species richness among restoration sites is less for vagile taxa than for sedentary taxa, and if invertebrates display greater variability among sites than vertebrates. Our results demonstrate that responses to restoration can vary depending upon the season when it is assessed, and the taxa that are studied. For all taxa except bees, there was considerable variability in the relative performance of taxa at restoration sites from one sampling date to the next, such that the relative ranking of the sites often changed dramatically. Comparisons of β ‐diversity (variability in species richness across sites) revealed that certain taxonomic groups were more spatially variable in their response to restoration than others. Among vertebrates, sedentary taxa (rodents) had significantly higher variability in species richness across sites than highly vagile taxa (birds); however, no such pattern was observed for invertebrates. Overall, vertebrates had lower variability than invertebrates, suggesting that evaluations of restoration success based on a few better‐known taxonomic groups (e.g., birds, rodents) may be inadequate to represent the biodiversity response of other groups (e.g., insects). 相似文献
86.
87.
Martin S Herder C Schloot NC Koenig W Heise T Heinemann L Kolb H;DIATOR Study Group 《PloS one》2011,6(3):e17554
Background
Recent evidence suggests that the lipid-lowering agent atorvastatin is also a potent immunomodulator. The aim of this study was to investigate the possible effect of atorvastatin on the decline of residual beta cell function in recent-onset type 1 diabetes.Methods and Findings
The randomised placebo-controlled Diabetes and Atorvastatin (DIATOR) Trial included 89 patients with newly diagnosed type 1 diabetes and islet autoantibodies (mean age 30 years, 40% females), in 12 centres in Germany. Patients received placebo or 80 mg/d atorvastatin for 18 months. As primary outcome stimulated serum C-peptide levels were determined 90 min after a standardized liquid mixed meal. An intent-to-treat analysis was performed. Fasting and stimulated C-peptide levels were not significantly different between groups at 18 months. However, median fasting serum C-peptide levels dropped from baseline to 12 and 18 months in the placebo group (from 0. 34 to 0.23 and 0.20 nmol/l, p<0.001) versus a nonsignificant decline in the atorvastatin group (from 0.34 to 0.27 and 0.30 nmol/l, ns). Median stimulated C-peptide concentrations declined between baseline and 12 months (placebo from 0.89 to 0.71 nmol/l, atorvastatin from 0.88 to 0.73 nmol/l, p<0.01 each) followed by a major loss by month 18 in the placebo group (to 0.48 nmol/l, p = 0.047) but not in the atorvastatin group (to 0.71 nmol/l, ns). Median levels of total cholesterol and C-reactive protein decreased in the atorvastatin group only (p<0.001 and p = 0.04). Metabolic control was similar between groups.Conclusions
Atorvastatin treatment did not significantly preserve beta cell function although there may have been a slower decline of beta-cell function which merits further study.Trial Registration
ClinicalTrials.gov NCT00974740相似文献88.
Koenig U Sommergruber W Lippens S 《Biochemical and biophysical research communications》2005,335(2):309-313
Cysteine-dependent aspartate-specific proteases (caspases) are the cellular executors of apoptosis. Caspase-14 is the most divergent member of the family of mammalian caspases and displays a variety of unique characteristics. It is expressed in a limited number of tissues and has the shortest amino acid sequence within the caspase protein family. During induction of apoptosis, it is not processed, whereas terminal differentiation in skin leads to cleavage of caspase-14. Here we show that 40% of lung squamous cell carcinomas, 22% of breast cancers, and about 80% of cervical carcinomas express caspase-14. Immunohistochemistry reveals that caspase-14 is localized in areas of ongoing differentiation close to necrotic sites but is not strictly associated with the differentiation markers keratin-1/-10. Caspase-14 is neither mutated nor alternatively spliced in the tumors analyzed. Furthermore, caspase-14 is not processed into a small and large subunit, a process critical for the proteolytic activation of known effector caspases. We conclude that conditions exist in tumors leading to re-expression of this normally silent gene. 相似文献
89.
Thyroid hormone plays important roles in development, differentiation, and metabolic homeostasis by binding to nuclear thyroid hormone receptors, which regulate target gene expression by interacting with DNA response elements and coregulatory proteins. We show that thyroid hormone receptors also are single-stranded RNA binding proteins and that this binding is functionally significant. By using a series of deletion mutants, a novel RNA-binding domain was localized to a 41-amino acid segment of thyroid hormone receptor alpha1 between the second zinc finger and the ligand-binding domain. This RNA-binding domain was necessary and sufficient for thyroid hormone receptor binding to the steroid receptor RNA activator (SRA). Although SRA does not bind directly to steroid receptors, it has been identified as a steroid receptor coactivator, and was thought not to be a coactivator for thyroid hormone receptors. However, transfection studies revealed that SRA enhances thyroid hormone induction of appropriate reporter genes and that the thyroid hormone receptor RNA-binding domain is important for this enhancement. We conclude that thyroid hormone receptors bind RNA through a novel domain and that the interaction of this domain with SRA, and perhaps other RNAs, enhances thyroid hormone receptor function. 相似文献
90.